Meriofert Set

Follicle-Stimulating Hormone; Luteinising Hormone, the active ingredient in Meriofert Set, is a gonadotropin presented as a sterile injectable solution for subcutaneous use. It is employed in assisted reproductive protocols to stimulate ovarian follicular development and trigger ovulation in women with infertility related to anovulation.

GNH USA supplies Meriofert Set as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, fertility clinics, reproductive endocrinology centres and procurement teams worldwide, ensuring quality‑controlled shipments and regulatory compliance across multiple markets, with a focus on timely delivery and product integrity.

Meriofert Set belongs to the gonadotropin class and is used in fertility‑related treatment pathways. - Anovulatory infertility: promotes follicular growth and induces ovulation. - Controlled ovarian stimulation for IVF/ICSI: enhances development of multiple follicles for assisted reproductive technology. - Ovulation induction in polycystic ovary syndrome: facilitates regular ovulation cycles.

Adverse reactions may occur with gonadotropin therapy and should be monitored.

Common Side Effects: - Injection site erythema: mild redness or swelling at the injection site. - Abdominal bloating: transient discomfort in the lower abdomen. - Headache: mild to moderate intensity. - Nausea: occasional feeling of queasiness.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome: severe swelling and fluid accumulation. - Multiple pregnancy: increased risk of twins or higher-order gestations. - Allergic reaction (including anaphylaxis): signs of rash, swelling, or breathing difficulty.

When using Meriofert Set, clinicians should observe several safety measures. - Monitor ovarian response: perform serial ultrasound and estradiol measurements. - Avoid use in active ovarian cysts: assess cyst status before initiation. - Adjust dose in renal impairment: follow prescriber guidance for dose modification. - Use caution in patients with a history of thromboembolism: evaluate individual risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert Set may interact with other hormonal or systemic agents.

Major Interactions (Avoid): - GnRH agonists: can cause excessive ovarian stimulation. - hCG therapy: overlapping LH activity may increase hyperstimulation risk. - Estrogen‑containing oral contraceptives: may antagonize gonadotropin effect.

Moderate Interactions (Monitor Closely): - Thyroid hormone replacement: may influence ovarian response. - Anticoagulants: monitor for bleeding complications if ovarian hyperstimulation occurs. - Corticosteroids: may alter hormone metabolism and affect treatment outcome.